Background COVID-19 is primarily known as a respiratory illness; however, many patients
present to hospital without respiratory symptoms. The association between non-respiratory …

Background The coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) continues to challenge the health …

Since December 2019, many drugs have been evaluated or advocated as potential
treatments of SARS-CoV-2 induced disease (COVID-19), including many repositioned drugs …

Abstract Introduction Despite Tocilizumab is now recognized as a concrete therapeutic
option in patients with severe SARS-CoV-2 related respiratory failure, literature lacks about …

Introduction Severe COVID‐19 management is still challenging. Having a laboratory factor
to predict the severity of a patient's condition can be very useful in how to approach each …

(1) Background: In COVID-19 patients, the occurrence of thromboembolic complications
contributes to disease progression and mortality. In patients at increased risk for thrombotic …

The hyperinflammatory phase represents the main cause for the clinical worsening of acute
respiratory distress syndrome (ARDS) in Coronavirus disease 2019 (COVID-19), leading to …

Objectives: In the context of COVID-19, patients with a severe or critical illness may be more
susceptible to developing secondary bacterial infections. This study aims to investigate the …

The human beta-coronavirus strain, OC43, provides a useful model for testing the antiviral
activity of various agents. We compared the activity of several antiviral drugs against OC43 …

Antimicrobial resistance (AMR), a serious global public health challenge, may have
accelerated development during the COVID-19 pandemic because antibiotics were …